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S_mmary Methoxymorpholinyl doxorubicin (MMDX) is a novel anti-cancer anthracycline that differs from
doxorubicin in its mechanisms of action, pattern of resistance and metabolism. Whereas doxorubicin is
primarily an inhibitor of topoisomerase II. MMDX inhibits both topoisomerases I and II. resulting in
predominantly single-strand DNA cleavage and, to a lesser extent. double-strand DNA breakage. MMDX is
equally cytotox.ic in vitro against the doxorubicin-sensitive and -resistant uterine sarcoma cell lines, MES-SA
and Dx5. Using fluorescent laser cytometry. MMDX was retained intracellularly to a similar extent in
MES-SA and Dx5; the intracellular retention of MMDX was 7.5-fold higher than that of doxorubicin in Dx5.
The cytotoxicity of MMDX on an ovarian carcinoma cell line, ES-2. was potentiated 50-fold by preincubating
the drug with human liver microsomes and NADPH. This cytotoxic potentiation was associated with the
appearance of DNA interstrand cross-links. The in vitro potentiation of MMDX was inhibited by cyclosporin
A. which is a substrate for human cytochrome P450 IIIA.
Since its introduction into clinical medicine in the early
1970s, doxorubicin has become an important anti-cancer
drug in the treatment of a variety of solid tumours (Blum &
Carter. 1974). However, its clinical uses are limited by car-
diomyopathy (Bristow et al.. 1978) and emergence of drug
resistance, particularly multidrug resistance (MDR) (Pastan
& Gottesman, 1987). Over the last 20 years. many anthra-
cycline analogues have been synthesised in an attempt to
circumvent the cardiotoxicity and drug resistance associated
with doxorubicin.
One promising series of anthracycine derivatives is the
morpholinyl analogues, which, compared with doxorubicin,
appear to be less cardiotoxic (Sikic et al., 1985) and more
cytotoxic against multidrug-resistant tumour cells (Streeter et
al., 1985; Watanabe et al., 1988). Methoxymorpholinyl doxo-
rubicin (MMDX) or FCE 23762 is a morpholinyl analogue
possessing a methoxymorpholinyl group at the 3' position of
the sugar moiety (Figure 1). MMDX is at least 80 times
more potent than doxorubicin against P388 leukaemia in
vivo, but only 3- to 4-fold more potent than doxorubicin in
vitro (Grandi et al., 1990). This compound also maintains in
vitro and in vivo cytotoxic activity against P388 leukaemia
resistant to doxorubicin (Ripamonti et al., 1992). In this
communication, we report that the in vivo potentiation of
MMDX is due to conversion of the parent compound, which
is a topoisomerase I and II inhibitor, to a metabolite(s) with
DNA-alkylating activity.
Materials and methods
Drugs
Doxorubicin hydrochloride was purchased from Adria
Laboratories (Columbus, OH, USA) and reconstituted in
sodium chloride injection (USP) as a I mM stock solution.
Methoxymorpholinyl doxorubicin hydrochloride was a gift
from Farmitalia Carlo Erba (Milan, Italy). The drug was
initially dissolved in absolute alcohol to a concentration of
0.1 mM followed by subsequent dilutions with culture
medium for cytotoxicity assays or appropriate diluent for
topoisomerase I and II assays. Cyclosporin A, 50 mg per
10 ml ampoule. was purchased from Sandoz Pharmaceuticals
(East Hanover, NJ, USA).
Cell culture
A human uterine sarcoma cell line, MES-SA, its doxorubicin-
resistant subline that expresses P-glycoprotein, Dx5 (Harker
& Sikic, 1985), and a human ovarian carcinoma cell line,
ES-2 (Lau et al., 1989), were grown as monolayers in
McCoy's 5A medium (Irvine Scientific, Santa Ana, CA,
USA) supplemented with 2 mM glutamine, 5 iLg ml-' insulin,
7.5% newborn calf serum, 100 U ml-' penicillin and
100 ig ml1' streptomycin (Gibco Laboratories, Grand
Island, NY, USA).
Microsomal incubation
Human liver microsomes were prepared, and incubation with
MMDX was performed as previously described (Lau et al.,
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1989). Brieflv. MMDX. at a concentration of S jim. was
incubated for 30 mn with 0.4 mg ml-' human liver micro-
somes and 0.4 mm NADPH in 2.5 ml of 0.3 M TIns buffer at
pH 7.4. For the inhibition study. the incubation mixture was
preincubated with 1-5jigml-' cyclosporin A for 20min
before MMDX was added. The mixture was centrifuged at
12,000 g for 10 min and the supernatant was filtered through
a 0.2 jim filter. The filtrate was used for MTT assay and
alkaline elution as described below.
Cviototoxicitv assay
The cytotoxicity of doxorubicin or MMDX was studied
using a modified MTT assay (Mosmann. 1983). The cells
were seeded into a 96-well microtitre plate and allowed to
attach overnight. The cells were then grown in various con-
centrations of each drug for 48 h. followed by incubating
with 5 mg ml-' 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tet-
razolium bromide (MTT) (Sigma. St Louis, MO. USA) for
2-3 h. Absorbance of the wells at 570 nm was determined as
previously described (Lau et al.. 1989). Percentage survival
was defined as the absorbance of the drug-treated wells
expressed as a percentage of that of controls.
Fluorescent laser c!itometrr
Intracellular retention of drug was studied by measuring
intracellular fluorescence using interactive laser cvtometrv.
Approximately 1.5 x l0 MES-SA or Dx5 cells were plated
and allowed to attach to a 3 cm culture dish overnight.
Doxorubicin or MMDX was added to the medium of the
culture dish to achieve a final drug concentration of 10jiM.
The culture dishes were incubated for 2 h in a cell culture
incubator at 37C. The medium was discarded and the dish
was rinsed with phosphate-buffered saline at 4°C. The dish
was immediately scanned using an ACAS 570 interactive
laser cytometer equipped with an Olympus IMT-2 inverted
microscope and an argon-ion laser as a light source. and
interphased with a 80386 computer system for data process-
ing and storage (Meridian Instruments. Okemos. MI. USA).
Intracellular fluorescent emission was detected by a photo-
multiplier tube as pixels which were digitalised by the com-
puter to represent relative intensity of the emission as
fluorescence values. Each dish was scanned at an excitation
wavelength of 488 nm for 180 steps with each step width of
2 mm at a scanning speed of 20mm s
Topoisomerases I and II assays
Induction of topoisomerase-mediated DNA cleavage was
studied using the Drug Screening Assay Kits supplied by
TopoGen (Columbus. OH. USA). For the topoisomerase I
assay. a 20 ji reaction mixture consisting of 0.25 jig of a
supercoiled pHOT plasmid (form I DNA) with a specific
cleavage site for topoisomerase I. 10 units of purified human
topoisomerase I and an appropriate volume of a drug stock
solution to achieve a final drug concentration of 0. 0.1. 0.5.
0.75 or 1.0 jiM -as incubated for 30min at 37C. Campto-
thecin. a known topoisomerase I inhibitor, was used as a
positive control for inhibition of this enzyme. The reaction
was stopped by adding IOOo SDS and 50jig ml ' proteinase K
followed by extraction with chloroform-isoamyl alcohol
(24:1. v v). and the aqueous layer was electrophoresed in a
100o agarose gel. For the topoisomerase II assay. the reaction
mixture consisted of 0.25 jg of a supercoiled pRYG plasmid
containing a single. high-affinity topoisomerase Il cleavage
and recognition site. 4 units of purified human topoisomerase
II and an appropriate volume of a drug stock solution to
yield a final drug concentration of 0. 0.1. 0.5. 0.75 or 1.0 pm.
The reaction was performed and analysed in the same man-
ner as described above. VM-26. a known topoisomerase II
inhibitor, was used as a positive control for inhibition of this
enzyme.
.4Akaline and neutral elutions
DNA single-strand breaks and DNA cross-links were
measured by alkaline elution. and DNA double breaks were
studied by neutral elution accordinz to a modified method of
Kohn et al. (1981) and Lau et al. (1989). For alkaline elution.
ES-2 cells were labelled with [methxl-'4C]thymidine (Amer-
sham. Arlington Heights. IL. USA). and exposed to MMDX.
with or without prior microsomal incubation, at concentra-
tions of 50-250 nM. at 37C for 2 h. The '4C-labelled cells
were irradiated with 300 cGy and the [methyl-3H]thymidine-
labelled internal standard cells with 400 cGy. Approximately
10.000 c.p.m. each of '4C-labelled and "H-labelled cells were
loaded onto a column mounted with a 2 jim polycarbonate
filter and the cells were lvsed with 2%o SDS and 0.02 M
EDTA at pH 10. followed by digestion with 0.5 mg ml-'
proteinase K. Elution buffer. consisting of 0.02 M EDTA and
0.1% SDS adjusted to pH 12.1 with tetrapropylammonium
hydroxide. was collected at a rate of 2 ml h-'. For neutral
elution. the internal standard cells were irradiated with
5.000 cGy. and the pH of the elution buffer was adjusted to
9.6. Fractions of 4C and "H radioactivitv retained on the
filter at 2 h elution intervals were determined. and the log
fraction of '4C retained was plotted against the corresponding
loz fraction of 'H retained. The number of DNA cross-links
in rad equivalents was calculated (Ewig & Kohn. 1978) using
the Excel program on a Macintosh microcomputer. The
numbers of single- and double-strand breaks in rad equiva-
lents were determined from a standard curve of elution slopes
versus radiation doses.
Results
C!totoxicit!'
The profile of dose and cytotoxicity of MMDX on MES-SA
and DxS is illustrated in Figure 2. The dose-response curves
for both cell lines were similar. giving an IC* (concentration
that inhibited cell growth by 5000) of 3 nm for MES-SA and
of 5 nm for DxS. In contrast. the ICy, values of doxorubicin
for MES-SA and DxS were 40 nm and 1.300 nm respectively
(Figure 3).
The cytotoxicity of MMDX preincubated with human liver
microsomes is shown in Figure 4. For ES-2 cells. the IC. of
MMDX preincubated with human microsomes in the ab-
sence of NADPH was 7 nm. which was essentially similar to
that of MMDX without preincubation. After preincubating
with human microsomes and NADPH. the IC*- value of
MMDX was markedly decreased to 0.13 nm. yielding a cyto-
toxic potentiation of 50-fold. This potentiation could be com-
pletely abolished by cvclosporin A at a concentration of
Ijigml-'.
Intracellular drug retention
After a 2 h exposure to doxorubicin. only a low level of
intracellular fluorescence was detectable in the multidrug-
resistant cells. Dx5. by the laser cytometer, as shown in
Figure 5a. In contrast, high levels of MMDX were seen
intracellularly in Dx5 cells as evidenced by the intense intra-
cellular fluorescence. especially in the nuclear region of each
cell (Figure Sb). The mean relative intracellular fluorescent
value (± s.e.) of doxorubicin was 9.988 ± 501 compared with
that of 75.363 + 1.888 for MMDX. giving a ratio of intracel-
lular MMDX to doxorubicin of 7.5. In comparison. the
multidrug-sensitive cells. MES-SA. acquired a mean relative
intracellular fluorescent value of doxorubicin of 38.190 +
1.808 and that of MMDX of 81.943 ± 2.788. giving a ratio of
intracellular MMDX to that of doxorubicin of 2.1 (Figures
Sc and Sd). These results indicate that MMDX is retained
intracellularly more avidly than doxorubicin. and to a similar
extent in the multidrug-sensitive and -resistant cells.METABOLIC CONVERSION OF MMDX
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Figure 2 Survival curves of MES-SA (0) and Dx5 cells (0) in
response to various doses of MMDX. Each value is the
mean±s.e. (n=4).
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Figure 3 SurVvial curves of MES-SA (0) and Dx5 cells (@) in
response to vanous doses of doxorubicin. Each value is the
mean±s.e. (n=4).
Fgure 5 a. Retention of doxorubicin by Dx5 cells as intracel-
lular fluorescence measured by laser cytometry at a wavelength of
488 nm. b. Retention of MMDX by Dx5 cells as intracellular
fluorescence measured by laser cytometry at a wavelength of
488 nm. c. Retention ofdoxorubicin by MES-SA cells as intracel-
lular fluorescence measured by laser cytometry at a wavelength of
488 nm. d. Retention of MMDX by MES-SA cells as intracellular
fluorescnce measured by laser cytometry at a wavelength of
488 nm.
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Figure 4 Survival curves of ES-2 cells in response to MMDX
without preincubation (0); MMDX preincubated with human
liver microsomes without NADPH (0): MMDX preincubated
with human liver microsomes plus NADPH (0); or MMDX
preincubated with human liver microsomes plus NADPH and
1 tg ml cyclosporin A. (A). Each value is a mean ± s.e.
(n = 4).
Topoisomerase assays
Drug-induced topoisomerase I-dependent DNA cleavage was
detected as an increase of nicked open circular DNA. This is
due to the stabilisation. by the drug, of the cleavable com-
plexes of a form I. supercoiled pHOT plasmid and a purified
human topoisomerase I. The patterns of topoisomerase I-
mediated DNA cleavage by camptothecin. doxorubicin and
MMDX are shown in Figure 6. Camptothecin. which is a
prototype topoisomerase I inhibitor, at concentrations of
0.1-0.2 mM increased the relative amount of open circular
DNA contained in the form I DNA. Doxorubicin, over a
Figure 6 Induction of topoisomerase I-mediated cleavage of a
form I DNA (a supercoiled pHOT plasrmid) by camptothecin
(CPT), doxorubicin (DOX) and methoxymorpholinyl doxorubicin
(MMDX). Top I. topoisomerase I; OC. open circular DNA. SC.
supercoiled DNA.
concentration range of 0.1 1 -IM. did not appear to have any
detectable effect on the topoisomerase I activity. For
MMDX, no effect was seen with low concentrations
(0.1-0.5gM). On the other hand, at concentrations of
0.75-1.0gM MMDX increased the formation of open cir-
cular DNA similar to that of camptothecim.
Topoisomerase 1I-mediated DNA cleavage was detected by
the conversion of the form I, supercoiled pRYG plasmid to
the relaxed DNA. This assay allowed detection of two types
of topoisomerase II inhibition: one was associated with pro-
moting formation of cleavable complexes and the other was
associated with antagonising binding of the enzyme to DNA.
VM-26. a known topoisomerase II inhibitor, converted a
supercoiled form I DNA to a cleavable complex appearing as
a linear DNA on the gel (Figure 7). Doxorubicin or MMDX.
at a concentration of 0.1 JAm, also induced formation of the
c d
80
60
40
20
ul)
z
x
cr
a:
Z z
0 0
E E
0 0
LL LL
oc
SC
n1
81
a 1(
E
E m
L-
= A
Ul)
.1
T
v l
I> >Z'82 D.H.M. LAU et al.
1.00
For- DNA - Topo 11 - Drug
i-
z
< VM26
z p .,
DOX
_.4
MMDX
_n
.0
c6 6) O'
Fge 7 Induction of topoisomerase 11-mediated cleavage of a
form I DNA (a supercoiled pRYG plasmid) by VM-26, doxo-
rubicin (DOX) and methoxymorpholinyl doxorubicin (MMDX).
Top II, topoisomerase II.
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Fugue 8 Alkline elution profile of ES-2 cells treated with: no
drug or radiation (0); 250 nm MMDX preincubated with human
liver microsomes and NADPH followed by 300cGy (0); 100 nm
MMDX preincubated with human liver microsomes and
NADPH followed by 300cGy (0): 300cGy alone (A): 250nM
MMDX without prior preincubation followed by 300cGy (U).
Each value is a mean of two experiments.
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cleavable complex. However, these drugs inhibited the forma-
tion of relaxed DNA or cleavable DNA complex at higher
concentrations ranging from 0.5 to 1.0 ElM.
Alkaline and neutral elutions
The alkaline elution profiles of ES-2 cells exposed to MMDX
under various conditions are shown in Figure 8. Compared
with cells exposed to irradiation alone, the elution rate of
DNA was higher for cells exposed to MMDX plus radiation,
indicating the presence of DNA strand breaks induced by the
drug. This strand breakage induced by MMDX is dose
dependent and protein associated, as digestion with pro-
teinase K unmasked over 90% of the breaks as illustrated in
Figure 9. It appears that the maximum strand cleavage was
reached at a dose of 500 nM.
Compared with doxorubicin, MMDX induced fewer
double-strand DNA breaks as measured by neutral elution.
At a concentration of 5 gM, 97 rad equivalents of double-
strand breaks were detected with MMDX, whereas 1,113 rad
equivalents were detected with doxorubicin (data not shown).
This indicates that MMDX, in contrast to doxorubicin,
preferentially induced DNA single-strand breakage. After
incubation with microsomes and NADPH, MMDX, at doses
of 100 and 250 nM, reduced the DNA elution rate, suggesting
the formation of DNA cross-links (Figure 8). The extent of
DNA cross-linking was directly related to the concentrations
of the MMDX preincubated with microsomes and NADPH,
as illustrated in Figure 10.
Methoxymorpholinyl doxorubicin is a novel analogue of dox-
orubicin with three unique biological characteristics distin-
guishing this compound from doxorubicin. Firstly, in both in
vitro and in vivo studies, MMDX is much more potent than
doxorubicin even in tumour cells which are resistant to doxo-
rubicin. Secondly, as compared with the topoisomerase II-
inhibiting activity of doxorubicin, MMDX is an inhibitor of
both topoisomerases I and II. Lastly, MMDX appears to be
metabolised by human microsomal enzymes to a DNA cross-
linking product with enhanced cytotoxicity.
As illustrated in this study, MMDX is a potent cytotoxin
in tumour cells resistant to doxorubicin. This enhanced
potency of MMDX can be explained by its higher intracel-
lular uptake and retention as demonstrated in this study by
laser cytometry. For the Dx5 cells, the potency ratio of
MMDX to doxorubicin (the ratio of the IC50 of doxorubicin
to that of MMDX) was 260, and the ratio of intracellular
fluorescent value of MMDX to that of doxorubicin was 7.5.
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Fugue 9 Dose dependence of MMDX in inducing DNA single-
strand breaks in rad equivalents in the presence (0) or absence
(0) of proteinase K.
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Fugue 10 Number of DNA cross-links (rad equivalents) in ES-2
cells exposed to various concentrations of MMDX preincubated
with human liver microsomes and NADPH.
For the MES-SA cells, these ratios were 13 and 2.1 respec-
tively. The preferential intracellular uptake of MMDX over
that of doxorubicin has also been demonstrated by the direct
measurement of intracellular drug concentrations (Grandi et
al., 1990). MMDX is relatively more lipophilic than doxo-
rubicin (Ripamonti et al., 1992). This higher lipophilicity may
allow rapid influx of the drug into cells, resulting in a high
intracellular concentration even in tumour cells with a
multidrug-resistant phenotype. The other lipophilic mor-
pholinyl anthracyclines, MX2 (Watanabe et al., 1988) and
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morpholinyl doxorubicin (Streeter et al.. 1986). have also
been reported to be equally cytotoxic against doxorubicin-
sensitive and -resistant cells. which is also thought to be
because of higher intracellular influx and retention of these
drugs in the resistant cells (Coley et al., 1993).
Doxorubicin inhibits topoisomerase II by DNA intercala-
tion and stabilisation of the DNA, topoisomerase II cleavable
complex. leading to double-strand DNA cleavage (Tewey et
al., 1984). MX2 also induces DNA double-strand breaks by
the same mechanism (Horichi et al., 1990). Morpholinyl
doxorubicin induces a pattern of topoisomerase I cleavage
sites of SV40 DNA different from that induced by campto-
thecin (Wassermann et al.. 1990). Uniquely. MMDX inhibits
both topoisomerases I and II. As confirmed by alkaline and
neutral elution studies, it preferentially causes protein-
associated DNA single-strand breakage compared with pro-
tein-associated DNA double-strand breakage. In vitro assay
of topoisomerase I indicated that MMDX increased the
DNA-cleavable complexes in a dose-dependent manner. For
the topoisomerase II assay. MMDX promoted the formation
of a DNA-cleavable complex or inhibited the catalytic
activity of topoisomerase II depending on the concentration
of the drug used. This inhibition of the topoisomerase II
activity at higher drug concentrations suggests that MMDX.
like doxorubicin. may also have DNA-intercalating activity.
Other new anti-cancer drugs with both topoisomerase I- and
II-inhibiting activities have also been reported recently (Cum-
mings & Smyth. 1993). These compounds include the lexi-
tropsins. the anthracenylpeptides and the imdoloquinolines.
Topoisomerases I and II are believed to play an important
role in DNA replication, transcription and recombination by
binding to DNA. inducing transient nicks followed by liga-
tion of the breaks (Liu. 1989). Inhibitors of topoisomerase I
or II are believed to bind to DNA topoisomerase cleavable
complexes and induce DNA breakage at specific sites. To
date, however. the preferred sites of DNA cleavage by
MMDX have not been determined.
Another important feature of MMDX is the fact that its
cytotoxicity can be markedly potentiated by preincubating
the drug with hepatic microsomes and NADPH. This poten-
tiation is associated with the appearance ofalkylating activity
of the metabolite(s) based on the alkaline elution study. This
metabolic conversion is believed to be mediated by the
human cytochrome P450 IIIA isoform since the potentiation
can be inhibited by cyclosporin A. a substrate of this P450
enzyme (Kronbach et al.. 1988). The metabolite with alkylat-
ing activity has yet to be identified. Our previous study with
morpholinyl doxorubicin showed a similar association of
metabolic potentiation and alkylating activity, which could
be abolished by the antibody and inhibitors of P450 IIIA
(Lau et al.. 1989; Lewis et al.. 1992). Although the active
metabolite of morpholinyl doxorubicin has not been identi-
fied, analysis of the reaction mixture by high-performance
liquid chromatography revealed the presence of a metabolite
with a functional group exchangeable with cyanide ion
leading to formation of cyanomorpholinyl doxorubicin
(Tracy et al.. 1990). This doxorubicin analogue has intrinsic
alkylating activity without requiring prior metabolic conver-
sion (Scudder et al.. 1988).
MMDX differs from doxorubicin in its efficacy against
multidrug-resistant tumour cells. a unique mechanism of
action as a topoisomerases I and II inhibitor. and potentia-
tion by metabolic conversion to an alkylator with DNA
cross-linking activity. However, the cardiotoxic potential of
MMDX is not known. Recent clinical trials with the campto-
thecin derivatives. topotecan and CPT-I I (Slichenmyer et al..
1993). which are topoisomerase I inhibitors, have shown a
promising spectrum of anti-cancer activities. especially in
non-small-cell lung cancer and gastrointestinal cancer. which
are inherently resistant to doxorubicin. The clinical safety
and efficacy of MMDX compared with the conventional
anthracyclines have yet to be determined by clinical trials.
This study was supported by American Cancer Society Grant
No. CH411 and Farmitalia Carlo Erba-
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